Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415306 | 1.00 | HRH3 (0.41) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| SCHEMBL1034237 | 1.00 | HRH3 (0.41) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| Hydrochloric Acid SCHEMBL15904240 | 0.98 | HRH3 (0.40) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| Hydrochloric Acid SCHEMBL29581714 | 0.98 | HRH3 (0.40) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| Ammonia Solution, Strong SCHEMBL19327469 | 0.98 | HRH3 (0.40) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| Hydrochloric Acid SCHEMBL31172943 | 0.98 | HRH3 (0.40) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| SCHEMBL39955 | 0.90 | TSHR (0.46) | HRH3GABRA5GABRB2TSHRGABRA1 | |
| SCHEMBL160676 | 0.89 | SLC6A1 (0.55) | HRH3TSHRSLC6A1SLC6A11SLC6A13 | |
| SCHEMBL25700006 | 0.89 | SLC6A1 (0.55) | HRH3TSHRSLC6A1SLC6A11SLC6A13 | |
| SCHEMBL160677 | 0.89 | SLC6A1 (0.55) | HRH3TSHRSLC6A1SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4598535-A2 | INHIBITORS OF SPNS2 AND USES THEREOF | New York University (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118930560-A | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| WO-2024210198-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2024-10-10 | — | — | WO | disclosed |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-09-12 | — | — | US | disclosed |
| EP-1322596-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030013714-A1 | Aryl sulfonamides and sulfamide derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-6391877-B1 | EATING DISORDERS; SEXUAL DISORDERS; ANTIDEPRESSANTS; ANTIEPILEPTIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2002024629-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6211241-B1 | ANTIDEPRESSANTS, SLEEP AND EATING DISORDERS AND ANTIEPILEPTIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| CN-1075963-A | The imidazolylpropenoic acid derivatives that Sulphonylbenzyl replaces | BAYER AG (DE) | 1993-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | HRH3 4294/4885GABRA5 4339/4885GABRB2 4314/4885 |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | HRH3 201/4885GABRA5 233/4885GABRB2 608/4885 |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | HRH3 3041/4885GABRA5 601/4885GABRB2 233/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | HRH3 4546/4885GABRA5 3301/4885GABRB2 3293/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HRH3 3264/4885GABRA5 3312/4885GABRB2 2704/4885 |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | HRH3 4294/4885GABRA5 4339/4885GABRB2 4314/4885 |
| US-20030013714-A1 | Aryl sulfonamides and sulfamide derivatives and uses thereof | NPY5R, SSTR5, NPY2R | HRH3 141/4885GABRA5 13/4885GABRB2 172/4885 |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | HRH3 1448/4885GABRA5 2998/4885GABRB2 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.